Article

Investigational New Drugs

, Volume 19, Issue 3, pp 245-247

First online:

Phase II Study of Bryostatin 1 in Patients with Relapsed Multiple Myeloma

  • Mary L. VarterasianAffiliated withKarmanos Cancer Institute, Wayne State University
  • , Pamela A. PembertonAffiliated withKarmanos Cancer Institute, Wayne State University
  • , Kim HulburdAffiliated withKarmanos Cancer Institute, Wayne State University
  • , Dorothy H. RodriguezAffiliated withKarmanos Cancer Institute, Wayne State University
  • , Anthony MurgoAffiliated withInvestigational Drug Branch, CTEP, DCTDC, NCI
  • , Ayad M. Al-KatibAffiliated withKarmanos Cancer Institute, Wayne State University

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Bryostatin 1, a macrocyclic lactoneisolated from the marine bryozoan Bugula neritina,is a protein kinase C (PKC) modulator which has shown bothpreclinical and clinical activity inlymphoid malignancies. We conducted aphase II trial of bryostatin 1 administeredat a dose of 120 μg/m2 by 72-hcontinuous infusion every 2 weeks inpatients with relapsed multiple myeloma. Treatment was well tolerated with myalgiasconstituting the primaray toxicity. Therewere no responses in nine evaluablepatients. The preclinical anti-lymphoidactivity is strong enough to supportfurther exploration of bryostatin 1 indifferent schedules and in combinationtherapy for multiple myeloma.

Phase II bryostatin 1 multiple myeloma relapsed